NCT04720092 - A Trial to Learn How a New Liquid Form of Rivaroxaban Behaves and How Safe it is Compared to the Current Tablet Form of Rivaroxaban in Healthy Male Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 5, 2017

Primary Completion Date

August 28, 2017

Study Completion Date

October 27, 2017

Conditions

Thromboembolic Disorders

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Granules for oral suspension, 10 mg, oral, single dose

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Tablet, 10 mg, oral, single dose

Trial Locations (1)

CRS Clinical-Research-Services Mönchengladbach GmbH, Mönchengladbach